Meibum Scientific announced the appointment of Ryan S. Bleeks as Interim Chief Executive Officer. The appointment comes as the company accelerates commercialization of its flagship technologies, BlephEx and OptiVize.

Mr. Bleeks brings more than two decades of ophthalmic industry expertise, with a career defined by strategic leadership, commercial success, and a deep network within the eye care community. Most recently, he served as CEO of Visiox Pharmaceuticals, where he oversaw the company’s definitive merger agreement with Ocuvex Therapeutics. He also led Visiox’s successful acquisition of the US license for Omlonti from Santen Pharmaceuticals, managing all phases of the transaction from negotiation through integration.

BlephEx is an in-office microblepharoexfoliation procedure used by providers for more than a decade to remove accumulated lid-margin biofilm and restore a healthier ocular surface environment. OptiVize is a next-generation intraglandular-vaporization and thermal expression platform designed to eliminate deeply embedded biofilm inside the meibomian glands.